Dihydroergotoxine Methanesulfonate

Dihydroergotoxine Methanesulfonate - General Information

Dihydroergotoxine Methanesulfonate is a dihydrogenated ergot (Claviceps purpurea) derivative alkaloid used as a vasodilator agent. Ergoloid Mesylate is the only vasodilator that has shown mild benefits in the treatment of vascular dementia.

Pharmacology of Dihydroergotoxine Methanesulfonate

Ergoloid Mesylate may increase cerebral metabolism and blood flow. The role of this medication in the therapy of dementia is controversial. A recent controlled study in patients with Alzheimer's disease found that there was no advantage to the use of ergoloid mesylates compared to placebo, suggesting that ergoloid mesylates may lower scores on some cognitive and behavioral rating scales. Further study is needed to determine the risk-benefit profile of ergoloid mesylates in the treatment of dementia.

Dihydroergotoxine Methanesulfonate for patients

Dihydroergotoxine Methanesulfonate Interactions

No reported interactions.

Dihydroergotoxine Methanesulfonate Contraindications

Ergoloid Mesylate is contraindicated for the treatment of patients with hypersensitivity to ergot preparations, or psychosis.

Additional information about Dihydroergotoxine Methanesulfonate

Dihydroergotoxine Methanesulfonate Indication: For use as an adjunct therapy for patients with dementia
Mechanism Of Action: Dihydroergotoxine Methanesulfonates act centrally, decreasing vascular tone and slowing the heart rate, and acts peripherally to block alpha-receptors. One other possible mechanism is the effect of ergoloid mesylates on neuronal cell metabolism, resulting in improved oxygen uptake and cerebral metabolism, thereby normalizing depressed neurotransmitter levels.
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Ergoloid mesylate
Synonyms: Not Available
Drug Category: Adrenergic alpha-Antagonists; Nootropic Agents; Vasodilator Agents; Sympatholytics
Drug Type: Small Molecule; Approved

Other Brand Names containing Ergoloid mesylate: Alkergot; Circanol; Co-Dergocrine Mesylate; Deapril-ST; Dihydroergotoxin Mesilat; Dihydroergotoxin Mesylate; Dihydroergotoxin Methanesulfonate; Dihydroergotoxine Mesilate; Dihydroergotoxine Mesylate; Dihydroergotoxine Methanesulfonate; Dihydroergotoxine Methanesulphonate; Ergoloid Mesylates [Usan]; Gerimal; Hydergin; Hydergine; Hydergine LC; Hydrogenated Ergot Alkaloids; Ischelium; Redergin; Trigot;
Absorption: Rapidly but incompletely (approximately 25%) absorbed from the gastrointestinal tract. Approximately 50% of the absorbed dose is eliminated by first-pass metabolism.
Toxicity (Overdose): Symptoms of overdose include dyspnea, hypotension or hypertension, rapid weak pulse, delirium, nausea, vomiting, and bradycardia.
Protein Binding: 98-99%
Biotransformation: Hepatic.
Half Life: 3.5 hours
Dosage Forms of Dihydroergotoxine Methanesulfonate: Tablet Oral
Chemical IUPAC Name: Not Available
Chemical Formula: C33H45N5O5
Ergoloid mesylate on Wikipedia: https://en.wikipedia.org/wiki/Ergoloid
Organisms Affected: Humans and other mammals